Skip to main content
Top
Published in: Medical Microbiology and Immunology 3/2010

Open Access 01-08-2010 | Review

CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation

Authors: Thomas Hünig, Fred Lühder, Karin Elflein, Tea Gogishvili, Monika Fröhlich, Reto Guler, Antony Cutler, Frank Brombacher

Published in: Medical Microbiology and Immunology | Issue 3/2010

Login to get access

Abstract

The costimulatory receptor CD28 and IL-4Rα-containing cytokine receptors play key roles in controlling the size and quality of pathogen-specific immune responses. Thus, CD28-mediated costimulation is needed for effective primary T-cell expansion and for the generation and activation of regulatory T-cells (Treg cells), which protect from immunopathology. Similarly, IL-4Rα signals are required for alternative activation of macrophages, which counteract inflammation by type 1 responses. Furthermore, immune modulation by CD28 and IL-4 is interconnected through the promotion of IL-4 producing T-helper 2 cells by CD28 signals. Using conditionally IL-4Rα and CD28 deleting mice, as well as monoclonal antibodies, which block or stimulate CD28, or mAb that deplete Treg cells, we have studied the roles of CD28 and IL-4Rα in experimental mouse models of virus (influenza), intracellular bacteria (L. monocytogenes, M. tuberculosis), and parasite infections (T. congolense, L. major). We observed that in some, but not all settings, Treg cells and type 2 immune deviation, including activation of alternative macrophages can be manipulated to protect the host either from infection or from immunopathology with an overall beneficial outcome. Furthermore, we provide direct evidence that secondary CD8 T-cell responses to i.c. bacteria are dependent on CD28-mediated costimulation.
Literature
1.
go back to reference Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD (2003) Interleukin-4 and interleukin-13 signaling connections maps. Science 300(5625):1527–1528PubMedCrossRef Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD (2003) Interleukin-4 and interleukin-13 signaling connections maps. Science 300(5625):1527–1528PubMedCrossRef
2.
go back to reference Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O’Hara RM Jr, Beier DR, Turner KJ, Wood CR, Collins M (1998) The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161(5):2317–2324PubMed Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O’Hara RM Jr, Beier DR, Turner KJ, Wood CR, Collins M (1998) The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161(5):2317–2324PubMed
3.
go back to reference Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12(1):99–106PubMedCrossRef Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12(1):99–106PubMedCrossRef
4.
go back to reference Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, Brombacher F (1999) Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 162(12):7302–7308PubMed Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, Brombacher F (1999) Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 162(12):7302–7308PubMed
5.
go back to reference Brombacher F (2000) The role of interleukin-13 in infectious diseases and allergy. Bioessays 22(7):646–656PubMedCrossRef Brombacher F (2000) The role of interleukin-13 in infectious diseases and allergy. Bioessays 22(7):646–656PubMedCrossRef
6.
go back to reference Shahinian A, Pfeffer K, Lee KP, Kündig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609PubMedCrossRef Shahinian A, Pfeffer K, Lee KP, Kündig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609PubMedCrossRef
7.
go back to reference Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12(4):431–440PubMedCrossRef Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12(4):431–440PubMedCrossRef
8.
go back to reference Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, Radwanska M, Leeto M, Kirsch R, Hall P, Mossmann H, Claussen B, Forster I, Brombacher F (2004) Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20(5):623–635PubMedCrossRef Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, Radwanska M, Leeto M, Kirsch R, Hall P, Mossmann H, Claussen B, Forster I, Brombacher F (2004) Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20(5):623–635PubMedCrossRef
9.
go back to reference Horsnell WG, Cutler AJ, Hoving JC, Mearns H, Myburgh E, Arendse B, Finkelman FD, Owens GK, Erle D, Brombacher F (2007) Delayed goblet cell hyperplasia, acetylcholine receptor expression, and worm expulsion in SMC-specific IL-4Ralpha-deficient mice. PLoS Pathog 3(1):e1PubMedCrossRef Horsnell WG, Cutler AJ, Hoving JC, Mearns H, Myburgh E, Arendse B, Finkelman FD, Owens GK, Erle D, Brombacher F (2007) Delayed goblet cell hyperplasia, acetylcholine receptor expression, and worm expulsion in SMC-specific IL-4Ralpha-deficient mice. PLoS Pathog 3(1):e1PubMedCrossRef
10.
go back to reference Leeto M, Herbert DR, Marillier R, Schwegmann A, Fick L, Brombacher F (2006) TH1-dominant granulomatous pathology does not inhibit fibrosis or cause lethality during murine schistosomiasis. Am J Pathol 169(5):1701–1712PubMedCrossRef Leeto M, Herbert DR, Marillier R, Schwegmann A, Fick L, Brombacher F (2006) TH1-dominant granulomatous pathology does not inhibit fibrosis or cause lethality during murine schistosomiasis. Am J Pathol 169(5):1701–1712PubMedCrossRef
11.
go back to reference Dewals B, Hoving JC, Leeto M, Marillier RG, Govender U, Cutler AJ, Horsnell WG, Brombacher F (2009) IL-4Ralpha responsiveness of non-CD4 T cells contributes to resistance in schistosoma mansoni infection in pan-T cell-specific IL-4Ralpha-deficient mice. Am J Pathol 175(2):706–716PubMedCrossRef Dewals B, Hoving JC, Leeto M, Marillier RG, Govender U, Cutler AJ, Horsnell WG, Brombacher F (2009) IL-4Ralpha responsiveness of non-CD4 T cells contributes to resistance in schistosoma mansoni infection in pan-T cell-specific IL-4Ralpha-deficient mice. Am J Pathol 175(2):706–716PubMedCrossRef
12.
go back to reference Dennehy KM, Elias F, Zeder-Lutz G, Ding X, Altschuh D, Luhder F, Hunig T (2006) Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol 176(10):5725–5729PubMed Dennehy KM, Elias F, Zeder-Lutz G, Ding X, Altschuh D, Luhder F, Hunig T (2006) Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol 176(10):5725–5729PubMed
13.
go back to reference Beyersdorf N, Ding X, Blank G, Dennehy KM, Kerkau T, Hunig T (2008) Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody. Blood 112(10):4328–4336PubMedCrossRef Beyersdorf N, Ding X, Blank G, Dennehy KM, Kerkau T, Hunig T (2008) Protection from graft-versus-host disease with a novel B7 binding site-specific mouse anti-mouse CD28 monoclonal antibody. Blood 112(10):4328–4336PubMedCrossRef
14.
go back to reference Gogishvili T, Elias F, Emery JL, McPherson K, Okkenhaug K, Hunig T, Dennehy KM (2008) Proliferative signals mediated by CD28 superagonists require the exchange factor Vav1 but not phosphoinositide 3-kinase in primary peripheral T cells. Eur J Immunol 38(9):2528–2533PubMedCrossRef Gogishvili T, Elias F, Emery JL, McPherson K, Okkenhaug K, Hunig T, Dennehy KM (2008) Proliferative signals mediated by CD28 superagonists require the exchange factor Vav1 but not phosphoinositide 3-kinase in primary peripheral T cells. Eur J Immunol 38(9):2528–2533PubMedCrossRef
15.
go back to reference Dolfi DV, Katsikis PD (2007) CD28 and CD27 costimulation of CD8+ T cells: a story of survival. Adv Exp Med Biol 590:149–170PubMedCrossRef Dolfi DV, Katsikis PD (2007) CD28 and CD27 costimulation of CD8+ T cells: a story of survival. Adv Exp Med Biol 590:149–170PubMedCrossRef
16.
go back to reference Dooms H, Abbas AK (2006) Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev 211:23–38PubMedCrossRef Dooms H, Abbas AK (2006) Control of CD4+ T-cell memory by cytokines and costimulators. Immunol Rev 211:23–38PubMedCrossRef
17.
go back to reference Borowski AB, Boesteanu AC, Mueller YM, Carafides C, Topham DJ, Altman JD, Jennings SR, Katsikis PD (2007) Memory CD8+ T cells require CD28 costimulation. J Immunol 179(10):6494–6503PubMed Borowski AB, Boesteanu AC, Mueller YM, Carafides C, Topham DJ, Altman JD, Jennings SR, Katsikis PD (2007) Memory CD8+ T cells require CD28 costimulation. J Immunol 179(10):6494–6503PubMed
18.
go back to reference Kursar M, Bonhagen K, Fensterle J, Kohler A, Hurwitz R, Kamradt T, Kaufmann SH, Mittrucker HW (2002) Regulatory CD4 + CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med 196(12):1585–1592PubMedCrossRef Kursar M, Bonhagen K, Fensterle J, Kohler A, Hurwitz R, Kamradt T, Kaufmann SH, Mittrucker HW (2002) Regulatory CD4 + CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med 196(12):1585–1592PubMedCrossRef
19.
go back to reference Tacke M, Hanke G, Hanke T, Hunig T (1997) CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 27(1):239–247PubMedCrossRef Tacke M, Hanke G, Hanke T, Hunig T (1997) CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 27(1):239–247PubMedCrossRef
20.
go back to reference Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hunig T (2003) Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197(8):955–966PubMedCrossRef Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hunig T (2003) Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197(8):955–966PubMedCrossRef
21.
go back to reference Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, Fennelly JA, Vowles C, Hanke T, Walse B, Hunig T, Sorensen P, Stuart DI, Davis SJ (2005) Crystal structure of a soluble CD28-Fab complex. Nat Immunol 6(3):271–279PubMedCrossRef Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, Fennelly JA, Vowles C, Hanke T, Walse B, Hunig T, Sorensen P, Stuart DI, Davis SJ (2005) Crystal structure of a soluble CD28-Fab complex. Nat Immunol 6(3):271–279PubMedCrossRef
22.
go back to reference Rodriguez-Palmero M, Hara T, Thumbs A, Hünig T (1999) Triggering of T-cell proliferation through CD28 induces GATA-3 and promotes T-helper type 2 differentiation in vitro and in vivo. Eur J Immunol 29:3914–3924PubMedCrossRef Rodriguez-Palmero M, Hara T, Thumbs A, Hünig T (1999) Triggering of T-cell proliferation through CD28 induces GATA-3 and promotes T-helper type 2 differentiation in vitro and in vivo. Eur J Immunol 29:3914–3924PubMedCrossRef
23.
go back to reference Lin C-H, Hunig T (2003) Efficient expansion of regulatory T-cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 33:626–638PubMedCrossRef Lin C-H, Hunig T (2003) Efficient expansion of regulatory T-cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 33:626–638PubMedCrossRef
24.
go back to reference Gogishvili T, Langenhorst D, Luhder F, Elias F, Elflein K, Dennehy KM, Gold R, Hunig T (2009) Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 4(2):e4643PubMedCrossRef Gogishvili T, Langenhorst D, Luhder F, Elias F, Elflein K, Dennehy KM, Gold R, Hunig T (2009) Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 4(2):e4643PubMedCrossRef
25.
go back to reference Hunig T (2007) Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 95:111–148PubMedCrossRef Hunig T (2007) Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 95:111–148PubMedCrossRef
26.
go back to reference Beaudette-Zlatanova BC, Whalen B, Zipris D, Yagita H, Rozing J, Groen H, Benjamin CD, Hunig T, Drexhage HA, Ansari MJ, Leif J, Mordes JP, Greiner DL, Sayegh MH, Rossini AA (2006) Costimulation and autoimmune diabetes in BB rats. Am J Transplant 6(5 Pt 1):894–902PubMedCrossRef Beaudette-Zlatanova BC, Whalen B, Zipris D, Yagita H, Rozing J, Groen H, Benjamin CD, Hunig T, Drexhage HA, Ansari MJ, Leif J, Mordes JP, Greiner DL, Sayegh MH, Rossini AA (2006) Costimulation and autoimmune diabetes in BB rats. Am J Transplant 6(5 Pt 1):894–902PubMedCrossRef
27.
go back to reference Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202(3):445–455PubMedCrossRef Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hunig T, Kerkau T, Gold R (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 202(3):445–455PubMedCrossRef
28.
go back to reference Azuma H, Isaka Y, Li X, Hunig T, Sakamoto T, Nohmi H, Takabatake Y, Mizui M, Kitazawa Y, Ichimaru N, Ibuki N, Ubai T, Inamoto T, Katsuoka Y, Takahara S (2008) Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 8(10):2004–2014PubMedCrossRef Azuma H, Isaka Y, Li X, Hunig T, Sakamoto T, Nohmi H, Takabatake Y, Mizui M, Kitazawa Y, Ichimaru N, Ibuki N, Ubai T, Inamoto T, Katsuoka Y, Takahara S (2008) Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 8(10):2004–2014PubMedCrossRef
29.
go back to reference Beyersdorf N, Ding X, Hunig T, Kerkau T (2009) Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. Blood 114(20):4575–4582PubMedCrossRef Beyersdorf N, Ding X, Hunig T, Kerkau T (2009) Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease. Blood 114(20):4575–4582PubMedCrossRef
30.
go back to reference Kitazawa Y, Fujino M, Li XK, Xie L, Ichimaru N, Okumi M, Nonomura N, Tsujimura A, Isaka Y, Kimura H, Hunig T, Takahara S (2009) Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. Cell Transplant 18(5):627–637PubMed Kitazawa Y, Fujino M, Li XK, Xie L, Ichimaru N, Okumi M, Nonomura N, Tsujimura A, Isaka Y, Kimura H, Hunig T, Takahara S (2009) Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. Cell Transplant 18(5):627–637PubMed
31.
go back to reference Kitazawa Y, Fujino M, Sakai T, Azuma H, Kimura H, Isaka Y, Takahara S, Hunig T, Abe R, Li XK (2008) Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 27(4):362–371PubMedCrossRef Kitazawa Y, Fujino M, Sakai T, Azuma H, Kimura H, Isaka Y, Takahara S, Hunig T, Abe R, Li XK (2008) Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody can prevent rat cardiac allograft rejection. J Heart Lung Transplant 27(4):362–371PubMedCrossRef
32.
go back to reference Elflein K, Rodriguez-Palmero M, Kerkau T, Hunig T (2003) Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 102(5):1764–1770PubMedCrossRef Elflein K, Rodriguez-Palmero M, Kerkau T, Hunig T (2003) Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 102(5):1764–1770PubMedCrossRef
33.
go back to reference Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028PubMedCrossRef Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028PubMedCrossRef
34.
go back to reference Rodriguez-Palmero M, Franch A, Castell M, Pelegri C, Perez-Cano FJ, Kleinschnitz C, Stoll G, Hunig T, Castellote C (2006) Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 33(1):110–118PubMed Rodriguez-Palmero M, Franch A, Castell M, Pelegri C, Perez-Cano FJ, Kleinschnitz C, Stoll G, Hunig T, Castellote C (2006) Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J Rheumatol 33(1):110–118PubMed
35.
go back to reference Guilliams M, Bosschaerts T, Herin M, Hunig T, Loi P, Flamand V, De Baetselier P, Beschin A (2008) Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis 198(5):781–791PubMedCrossRef Guilliams M, Bosschaerts T, Herin M, Hunig T, Loi P, Flamand V, De Baetselier P, Beschin A (2008) Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis 198(5):781–791PubMedCrossRef
36.
go back to reference Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988) Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168(5):1675–1684PubMedCrossRef Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988) Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168(5):1675–1684PubMedCrossRef
37.
go back to reference Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, Hassanzadeh Gh G (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol 71(4):597–602PubMed Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, Hassanzadeh Gh G (2002) Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol 71(4):597–602PubMed
38.
go back to reference Mountford AP, Hogg KG, Coulson PS, Brombacher F (2001) Signaling via interleukin-4 receptor alpha chain is required for successful vaccination against schistosomiasis in BALB/c mice. Infect Immun 69(1):228–236PubMedCrossRef Mountford AP, Hogg KG, Coulson PS, Brombacher F (2001) Signaling via interleukin-4 receptor alpha chain is required for successful vaccination against schistosomiasis in BALB/c mice. Infect Immun 69(1):228–236PubMedCrossRef
39.
go back to reference Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, Bogaert P, Boonefaes T, Kindt A, Van den Bergh R, Leenen PJ, De Baetselier P, Ghassabeh GH (2005) Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol 77(3):321–327PubMedCrossRef Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noel W, Bogaert P, Boonefaes T, Kindt A, Van den Bergh R, Leenen PJ, De Baetselier P, Ghassabeh GH (2005) Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol 77(3):321–327PubMedCrossRef
40.
go back to reference Linehan SA, Coulson PS, Wilson RA, Mountford AP, Brombacher F, Martinez-Pomares L, Gordon S (2003) IL-4 receptor signaling is required for mannose receptor expression by macrophages recruited to granulomata but not resident cells in mice infected with Schistosoma mansoni. Lab Invest 83(8):1223–1231PubMedCrossRef Linehan SA, Coulson PS, Wilson RA, Mountford AP, Brombacher F, Martinez-Pomares L, Gordon S (2003) IL-4 receptor signaling is required for mannose receptor expression by macrophages recruited to granulomata but not resident cells in mice infected with Schistosoma mansoni. Lab Invest 83(8):1223–1231PubMedCrossRef
41.
go back to reference Noel W, Hassanzadeh G, Raes G, Namangala B, Daems I, Brys L, Brombacher F, Baetselier PD, Beschin A (2002) Infection stage-dependent modulation of macrophage activation in trypanosoma congolense-resistant and -susceptible mice. Infect Immun 70(11):6180–6187PubMedCrossRef Noel W, Hassanzadeh G, Raes G, Namangala B, Daems I, Brys L, Brombacher F, Baetselier PD, Beschin A (2002) Infection stage-dependent modulation of macrophage activation in trypanosoma congolense-resistant and -susceptible mice. Infect Immun 70(11):6180–6187PubMedCrossRef
42.
go back to reference Ghassabeh GH, De Baetselier P, Brys L, Noel W, Van Ginderachter JA, Meerschaut S, Beschin A, Brombacher F, Raes G (2006) Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood 108(2):575–583PubMedCrossRef Ghassabeh GH, De Baetselier P, Brys L, Noel W, Van Ginderachter JA, Meerschaut S, Beschin A, Brombacher F, Raes G (2006) Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood 108(2):575–583PubMedCrossRef
43.
go back to reference Hölscher C, Arendse B, Schwegmann A, Myburgh E, Brombacher F (2005) Impairment of alternative macrophage activation delays cutaneous leishmaniasis in non-healing BALB/c mice. J Immunol 176:1115–1121 Hölscher C, Arendse B, Schwegmann A, Myburgh E, Brombacher F (2005) Impairment of alternative macrophage activation delays cutaneous leishmaniasis in non-healing BALB/c mice. J Immunol 176:1115–1121
44.
go back to reference Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N, Straubinger RK, Blessing M, McKenzie AN, Brombacher F, Alber G (2007) IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 179(8):5367–5377PubMed Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N, Straubinger RK, Blessing M, McKenzie AN, Brombacher F, Alber G (2007) IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 179(8):5367–5377PubMed
45.
go back to reference Stenzel W, Muller U, Kohler G, Heppner FL, Blessing M, McKenzie AN, Brombacher F, Alber G (2009) IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol 174(2):486–496PubMedCrossRef Stenzel W, Muller U, Kohler G, Heppner FL, Blessing M, McKenzie AN, Brombacher F, Alber G (2009) IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol 174(2):486–496PubMedCrossRef
46.
go back to reference Cao Y, Brombacher F, Tunyogi-Csapo M, Glant TT, Finnegan A (2007) Interleukin-4 regulates proteoglycan-induced arthritis by specifically suppressing the innate immune response. Arthritis Rheum 56(3):861–870PubMedCrossRef Cao Y, Brombacher F, Tunyogi-Csapo M, Glant TT, Finnegan A (2007) Interleukin-4 regulates proteoglycan-induced arthritis by specifically suppressing the innate immune response. Arthritis Rheum 56(3):861–870PubMedCrossRef
47.
go back to reference Keating P, O’Sullivan D, Tierney JB, Kenwright D, Miromoeini S, Mawasse L, Brombacher F, La Flamme AC (2009) Protection from EAE by IL-4Ralpha(-/-) macrophages depends upon T regulatory cell involvement. Immunol Cell Biol 87(7):534–545PubMedCrossRef Keating P, O’Sullivan D, Tierney JB, Kenwright D, Miromoeini S, Mawasse L, Brombacher F, La Flamme AC (2009) Protection from EAE by IL-4Ralpha(-/-) macrophages depends upon T regulatory cell involvement. Immunol Cell Biol 87(7):534–545PubMedCrossRef
48.
go back to reference Brys L, Beschin A, Raes G, Ghassabeh GH, Noel W, Brandt J, Brombacher F, De Baetselier P (2005) Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 174(10):6095–6104PubMed Brys L, Beschin A, Raes G, Ghassabeh GH, Noel W, Brandt J, Brombacher F, De Baetselier P (2005) Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol 174(10):6095–6104PubMed
49.
go back to reference Pesce JT, Ramalingam TR, Wilson MS, Mentink-Kane MM, Thompson RW, Cheever AW, Urban JF Jr, Wynn TA (2009) Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog 5(4):e1000393PubMedCrossRef Pesce JT, Ramalingam TR, Wilson MS, Mentink-Kane MM, Thompson RW, Cheever AW, Urban JF Jr, Wynn TA (2009) Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog 5(4):e1000393PubMedCrossRef
50.
go back to reference Barner M, Mohrs M, Brombacher F, Kopf M (1998) Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr Biol 8(11):669–672PubMedCrossRef Barner M, Mohrs M, Brombacher F, Kopf M (1998) Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr Biol 8(11):669–672PubMedCrossRef
51.
go back to reference Marillier RG, Michels C, Smith EM, Fick LC, Leeto M, Dewals B, Horsnell WG, Brombacher F (2008) IL-4/IL-13 independent goblet cell hyperplasia in experimental helminth infections. BMC Immunol 9:11PubMedCrossRef Marillier RG, Michels C, Smith EM, Fick LC, Leeto M, Dewals B, Horsnell WG, Brombacher F (2008) IL-4/IL-13 independent goblet cell hyperplasia in experimental helminth infections. BMC Immunol 9:11PubMedCrossRef
52.
go back to reference Radwanska M, Cutler AJ, Hoving JC, Magez S, Holscher C, Bohms A, Arendse B, Kirsch R, Hunig T, Alexander J, Kaye P, Brombacher F (2007) Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog 3(5):e68PubMedCrossRef Radwanska M, Cutler AJ, Hoving JC, Magez S, Holscher C, Bohms A, Arendse B, Kirsch R, Hunig T, Alexander J, Kaye P, Brombacher F (2007) Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog 3(5):e68PubMedCrossRef
Metadata
Title
CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation
Authors
Thomas Hünig
Fred Lühder
Karin Elflein
Tea Gogishvili
Monika Fröhlich
Reto Guler
Antony Cutler
Frank Brombacher
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Medical Microbiology and Immunology / Issue 3/2010
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-010-0156-z

Other articles of this Issue 3/2010

Medical Microbiology and Immunology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine